Tocilizumab Treatment for Nephrotic Syndrome Due to Amyloidosis in Behcet's Disease. (May 2013)

• Record Type: Journal Article
• Authors: Redondo-Pachón, M.D.; Enríquez, R.; Sirvent, A.E.; Andrada, E.; Noguera-Pons, R.; Millán, I.; Amorós, F.
• Is Part Of: Renal failure. Volume 35:Number 4(2013)
• Page Start: 547
• Page End: 550
• Publication Date: 2013-05
• Subjects: Chronic renal failure -- Periodicals; Acute renal failure -- Periodicals; Uremia -- Periodicals; 616.614005
• DOI: 10.3109/0886022X.2013.773913
• Languages: English
• ISSNs: 0886-022X

Abstract

<abstract> <title> <x xml:space="preserve">Abstract</x> </title> <p>Renal involvement is an unusual but significant Behcet´s disease (BD) complication and AA amyloidosis appears to be the most common etiology. IL-6 is a pro-inflammatory cytokine with an important role in AA amyloidosis development. Tocilizumab (TCZ) is a humanized anti-IL-6 receptor antibody that has emerged as an effective and specific treatment in AA amyloidosis secondary to chronic inflammatory disorders. We report on a patient diagnosed with BD who developed nephrotic syndrome caused by renal AA amyloidosis with an excellent response to TCZ therapy.</p> </abstract>